- Stocks
- Pharma & Healthcare
- Amkay Products
Amkay Products share price
NSE: AMKAYPharma & HealthcareMedical Instruments & Supplies
Amkay Products at a glance
With a market capitalisation of ₹46 Cr, it ranks 3119th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Instruments & Supplies.
Its return on equity was 8.8% in FY26. Promoters held 73.44% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹46 CrRank 3119 on NSE
- Price to book
- 1.71×FY26
- ROE
- 8.8%FY26
- ROCE
- 13.4%FY26
- Debt to equity
- 0.15FY26
- Net profit margin
- 5.5%FY26
- Book value / share
- ₹30.47FY26
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Amkay Products financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹41 Cr | ₹37 Cr | ₹28 Cr | ₹31 Cr | ₹38 Cr | ₹42 Cr |
| Operating profit | ₹4 Cr | ₹2 Cr | ₹2 Cr | ₹4 Cr | ₹4 Cr | ₹3 Cr |
| Net profit | ₹3 Cr | ₹1 Cr | ₹2 Cr | ₹3 Cr | ₹3 Cr | ₹2 Cr |
| EPS (₹) | ₹4.91 | ₹2.31 | ₹2.37 | ₹4.13 | ₹3.96 | ₹2.67 |
| Cash from operations | ₹3 Cr | −₹0 Cr | ₹1 Cr | −₹1 Cr | −₹0 Cr | ₹1 Cr |
| Total debt | ₹1 Cr | ₹3 Cr | ₹3 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr |
| Shareholders' equity | ₹5 Cr | ₹6 Cr | ₹8 Cr | ₹10 Cr | ₹24 Cr | ₹26 Cr |
Amkay Products shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 73.44% | 73.44% | 73.44% | 73.44% | 73.44% | 73.44% |
| Non-institutions | 26.56% | 26.56% | 26.56% | 26.56% | 26.56% | 26.56% |
Amkay Products vs peers
The listed Pharma & Healthcare companies nearest to Amkay Products by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| SHREEPACShree Pacetroni | — | — | — | ₹50 Cr | — | — |
| BIOFILCHEMBiofil Chemicals & Pharmaceuticals | ₹30.00 | +2.15% | −27.3% | ₹49 Cr | 17.5 | — |
| SHANMUGAShanmuga Hospit | — | — | — | ₹48 Cr | — | — |
| MANGALAMMangalam Drugs And Organics | ₹29.66 | −3.07% | −58.5% | ₹47 Cr | — | — |
| AMKAYAmkay Products | — | — | — | ₹46 Cr | — | — |
| SHELTERShelter Pharma | — | — | — | ₹46 Cr | — | — |
| VISTAPHVista Pharma | — | — | — | ₹45 Cr | — | — |
Ask anything about Amkay Products
Pivot answers on the live chart with evidence you can check, and tests strategies against AMKAY's own history. Try: “Why has AMKAY moved over the last three months?” · “Backtest a 50-day moving-average crossover on AMKAY over five years” · “Compare AMKAY with SHREEPAC on margins and valuation”
Frequently asked questions about Amkay Products
What is the market cap of Amkay Products?
Amkay Products' market capitalisation is ₹46 Cr (₹46 Cr) at the 22 Oct 2026 close, ranking 3119th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Amkay Products?
Return on equity was 8.8% in FY26 and return on capital employed was 13.4% in FY26 (standalone figures).
Is Amkay Products a debt-free company?
No. Amkay Products' debt-to-equity ratio was 0.15 in FY26, with total debt of ₹1 Cr.
What is the shareholding pattern of Amkay Products?
As of 30 Jun 2026: promoters 73.44%, non-institutions 26.56%.
Who are Amkay Products' competitors?
The listed Pharma & Healthcare companies closest to Amkay Products by market cap are Shree Pacetroni, Biofil Chemicals & Pharmaceuticals, Shanmuga Hospit, Mangalam Drugs And Organics, Shelter Pharma and Vista Pharma.
Is Amkay Products a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Amkay Products' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on AMKAY against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with A · all NSE stocks · this page as text